Our preclinical data provide strong rationale for this dual RAF-MEK inhibition strategy, which could represent a significant advance for patients with these challenging genetic driver mutations including Class II and III BRAF mutations, and may extend to other contexts such as different forms of mutant RAS in lung cancer and potentially other tumor types. This evidence concerns the gene RAF1 and lung carcinoma.